JDP Therapeutics, Inc. Appoints Christopher M. Cashman to Board of Directors

Share Article

JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today the appointment of Christopher M. Cashman to its Board of Directors. Mr. Cashman has an impressive track record in heading start-up pharmaceutical companies and advancing them to exit in addition to having over 30 years of industry experience.

The timing for Chris to join our team is especially fitting as we are now poised to move our flagship product into Phase I clinical trial development.

JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today the appointment of Christopher M. Cashman to its Board of Directors. Mr. Cashman has an impressive track record in heading start-up pharmaceutical companies and advancing them to exit in addition to having over 30 years of industry experience.

"Chris has been an invaluable advisor to JDP since its inception working along side founder Jie Du, Ph.D. for the past two years. He has played an integral role in the company’s success to date and we are thrilled that Chris has decided to become a formal member of the team,” said Josh Tarnoff, JDP’s CEO and Executive Board Member. “On a personal note, he is highly respected and well known for his strong integrity and relationships in both the corporate and investment communities.”

Christopher Cashman is co-founder of Protez Pharmaceuticals Inc. and served as Director, President and CEO. Protez was acquired by Novartis in 2008. He was the recipient of the “Entrepreneur of the Year” award at the 2008 MAC Alliance Conference and the “Life Sciences CEO of the Year” by the Eastern Technology Council. He currently also serves on the Board of Directors of Noble Biomaterials, MBF Therapeutics and the Science Center.

“It has been a pleasure working with Jie on the start-up phase of JDP, and now with Josh on board as CEO, JDP is well positioned to advance JDP-205 into the clinic,” said Mr. Cashman.

Company founder Jie Du, Ph.D. added, “The timing for Chris to join our team is especially fitting as we are now poised to move our flagship product into Phase I clinical trial development. We are excited that he will continue to share in our growth and help guide the Board through this very important phase.”

JDP Therapeutics Inc., founded in 2008, is a specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for acute care use in the hospital setting.

For further information, please call 215-661-8557 or email info(at)jdptherapeutics(dot)com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Josh Tarnoff
Visit website